Table 3.
Pulmonary Exacerbations: Microbiologic Characteristics
| Characteristic |
Total
(N=73)a |
Mild
(N=41)a |
Moderate/Severe
(N=32)a |
|||
|---|---|---|---|---|---|---|
| Pathogen growth | ||||||
| MSSA only | 39 | (53.42) | 25 | (60.98) | 14 | (43.75) |
| MRSA only | 12 | (16.44) | 7 | (17.07) | 5 | (15.63) |
| Pseudomonas aeruginosa only | 4 | (5.48) | 1 | (2.44) | 3 | (9.38) |
| MSSA, P. aeruginosa | 1 | (1.37) | 0 | (0.00) | 1 | (3.13) |
| MRSA, P. aeruginosa | 7 | (9.59) | 1 | (2.44) | 6 | (18.75) |
| P. aeruginosa, Stenotrophomonas
maltophilia |
1 | (1.37) | 1 | (2.44) | 0 | (0.00) |
| MSSA, S. maltophilia, Burkholderia
cepacia |
1 | (1.37) | 1 | (2.44) | 0 | (0.00) |
| MRSA, P. aeruginosa, S.
maltophilia |
1 | (1.37) | 1 | (2.44) | 0 | (0.00) |
| None | 7 | (9.59) | 4 | (9.76) | 3 | (9.38) |
| Outpatient antibioticb | ||||||
| Trimethoprim-sulfamethoxazole | 22 | (30.14) | 22 | (53.66) | 0 | (0.00) |
| Quinolones | 32 | (43.84) | 32 | (78.05) | 0 | (0.00) |
| Beta-lactams | 3 | (4.11) | 3 | (7.32) | 0 | (0.00) |
| Other | 6 | (8.22) | 6 | (14.63) | 0 | (0.00) |
| Inpatient antibioticb | ||||||
| Anti-pseudomonal beta-lactams | 29 | (39.73) | 0 | (0.00) | 29 | (90.62) |
| Carbapenem | 2 | (2.74) | 0 | (0.00) | 2 | (6.25) |
| Ceftaroline | 1 | (1.37) | 0 | (0.00) | 1 | (3.12) |
| Aminoglycosides | 29 | (39.73) | 0 | (0.00) | 29 | (90.62) |
| Vancomycin | 15 | (20.55) | 0 | (0.00) | 15 | (46.87) |
| Clindamycin | 1 | (1.37) | 0 | (0.00) | 1 | (3.12) |
| Quinolones | 4 | (5.48) | 0 | (0.00) | 4 | (12.5) |
| Trimethoprim-sulfamethoxazole | 3 | (4.11) | 0 | (0.00) | 3 | (9.37) |
| Other | 2 | (2.74) | 0 | (0.00) | 2 | (6.25) |
a
: Results represented as n(%).
b
: At some exacerbations, more than 1 antibiotic was given; thus, the sum of percentages exceeds 100%.